NASDAQ: ADMAAdma Biologics Inc Stock
$3.53-0.05 (-1.4%)
Updated Oct 2, 2023
ADMA Price
$3.53
Fair Value Price
$3.84
Market Cap
$793.92M
52 Week Low
$2.44
52 Week High
$4.65
P/E
-17.65x
P/B
5.41x
P/S
3.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$208.11M
Earnings
-$40.29M
Gross Margin
27.4%
Operating Margin
-7.96%
Profit Margin
-19.4%
Debt to Equity
1.34
Operating Cash Flow
-$41M
Beta
0.87
Next Earnings
Nov 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ADMA Overview
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADMA ($3.53) is undervalued by 8.12% relative to our estimate of its Fair Value price of $3.84 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADMA ($3.53) is not significantly undervalued (8.12%) relative to our estimate of its Fair Value price of $3.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADMA due diligence checks available for Premium users.
Be the first to know about important ADMA news, forecast changes, insider trades & much more!
ADMA News
Valuation
ADMA fair value
Fair Value of ADMA stock based on Discounted Cash Flow (DCF)
Price
$3.53
Fair Value
$3.84
Undervalued by
8.12%
ADMA ($3.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADMA ($3.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.65x
Industry
14.19x
Market
12.38x
ADMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.41x
Industry
5.05x
ADMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADMA's financial health
Profit margin
Revenue
$60.1M
Net Income
-$6.4M
Profit Margin
-10.6%
ADMA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADMA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$343.0M
Liabilities
$196.3M
Debt to equity
1.34
ADMA's short-term assets ($266.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMA's short-term assets ($266.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$872.6k
Financing
$240.1k
ADMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADMA vs Biotech Stocks
Adma Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.